Literature DB >> 31655220

Impact microindentation assesses subperiosteal bone material properties in humans.

Stamatia Rokidi1, Natalie Bravenboer2, Sonja Gamsjaeger1, Barbara Misof1, Stéphane Blouin1, Pascale Chavassieux3, Klaus Klaushofer1, Eleftherios Paschalis4, Socrates Papapoulos2, Natasha Appelman-Dijkstra2.   

Abstract

Impact microindentation (IMI) is a Reference Point Indentation technique measuring tissue-level properties of cortical bone in humans in vivo. The nature, however, of the properties that can affect bone strength is incompletely understood. In the present study we examined bone material properties in transiliac bone biopsies obtained concurrently with measurements of Bone Material Strength index (BMSi) by IMI in 12 patients with different skeletal disorders and a wide range of BMD, with or without fractures (8 males, 4 females, mean age 48±12.2 (SD) years, range 15-60 years). IMI was performed in the mid-shaft of the right tibia with a hand-held microindenter (OsteoProbe). Cancellous and cortical bone mineralization density distributions (BMDD) were measured in the entire biopsy bone area by quantitative backscattered electron imaging. Raman measurements were obtained right at the outer edge of the cortex, and 5, 50, 100, 500μm inwards. The calculated parameters were: i) Mineral and organic matrix content as well as the mineral / matrix ratio. ii) Nanoporosity. iii) Glycosaminoglycan content. iv) Pyridinoline content. v) Maturity/crystallinity of the apatite crystallites. There was no relationship between BMSi values with any measurement of mineral content of whole bone tissue (BMD, BMDD) or maturity/crystallinity of bone mineral. On the other hand, a positive correlation between BMSi and local mineral content, and an inverse correlation between BMSi and nanoporosity at the mineralized subperiosteal edge of the sample and at 5μm inwards was found. A positive correlation was also observed between BMSi and pyridinoline content at the same locations. These results indicate that local mineral content, nanoporosity and pyridinoline content at the subperiosteal site in the transiliac bone biopsy are linked to the BMSi values measured in the tibia. As both high porosity at the nano level and low pyridinoline content of the bone matrix can negatively impact bone strength, our findings suggest that BMSi most likely assesses subperiosteal bone material properties.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone matrix; Collagen; Fracture risk assessment; Iliac crest biopsies; MicroIndentation; Noncollagenous proteins; Raman analysis

Mesh:

Year:  2019        PMID: 31655220     DOI: 10.1016/j.bone.2019.115110

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  4 in total

1.  Treatments of osteoporosis increase bone material strength index in patients with low bone mass.

Authors:  M Schoeb; F Malgo; J J M Peeters; E M Winter; S E Papapoulos; N M Appelman-Dijkstra
Journal:  Osteoporos Int       Date:  2020-04-08       Impact factor: 4.507

2.  Bone material strength index as measured by in vivo impact microindentation is normal in subjects with high-energy trauma fractures.

Authors:  M Schoeb; E M Winter; F Malgo; I B Schipper; R J P van der Wal; S E Papapoulos; N M Appelman-Dijkstra
Journal:  Osteoporos Int       Date:  2022-03-21       Impact factor: 5.071

3.  Bone Material Strength Index as Measured by Impact Microindentation is Low in Patients with Primary Hyperparathyroidism.

Authors:  Manuela Schoeb; Elizabeth M Winter; Maria A Sleddering; Mirjam A Lips; Abbey Schepers; Marieke Snel; Natasha M Appelman-Dijkstra
Journal:  J Clin Endocrinol Metab       Date:  2021-06-16       Impact factor: 5.958

4.  Added Value of Impact Microindentation in the Evaluation of Bone Fragility: A Systematic Review of the Literature.

Authors:  Manuela Schoeb; Neveen A T Hamdy; Frank Malgo; Elizabeth M Winter; Natasha M Appelman-Dijkstra
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-07       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.